Comparative transcriptome analysis of dioecious, unisexual floral development in Ribes diacanthum pall

Unlocking the Hidden Genetic Diversity of Varicosaviruses, the Neglected Plant Rhabdoviruses

The genus Varicosavirus is one of six genera of plant-infecting rhabdoviruses. Varicosaviruses have non-enveloped, flexuous, rod-shaped virions and a negative-sense, single-stranded RNA genome. A distinguishing feature of varicosaviruses, which is shared with dichorhaviruses, is a bi-segmented genome. Before 2017, a sole varicosavirus was known and characterized, and then two more varicosaviruses were identified through high-throughput sequencing in 2017 and 2018. More recently, the number of known varicosaviruses has substantially increased in concert with the extensive use of high-throughput sequencing platforms and data mining approaches. The novel varicosaviruses have revealed not only sequence diversity, but also plasticity in terms of genome architecture, including a virus with a tentatively unsegmented genome. Here, we report the discovery of 45 novel varicosavirus genomes which were identified in publicly available metatranscriptomic data. The identification, assembly, and curation of the raw Sequence Read Archive reads has resulted in 39 viral genome sequences with full-length coding regions and 6 with nearly complete coding regions. The highlights of the obtained sequences include eight varicosaviruses with unsegmented genomes, which are linked to a phylogenetic clade associated with gymnosperms. These findings have resulted in the most complete phylogeny of varicosaviruses to date and shed new light on the phylogenetic relationships and evolutionary landscape of this group of plant rhabdoviruses. Thus, the extensive use of sequence data mining for virus discovery has allowed us to unlock of the hidden genetic diversity of varicosaviruses, the largely neglected plant rhabdoviruses.

Genus Ribes Linn. (Grossulariaceae): A comprehensive review of traditional uses, phytochemistry, pharmacology and clinical applications

ETHNOPHARMACOLOGICAL RELEVANCE

The genus Ribes Linn., which belongs to the Grossulariaceae family, contains 160 species distributed mainly in temperate and cold regions of the Northern Hemisphere. There are 59 species in southwest, northwest and northeast China. Some species of Ribes have been used as traditional and local medicines for the treatment of glaucoma, cardiovascular disease, stomachache, hepatitis, hyperlipidemia, hypertension and other ailments. However, the data provided in recent years have not been collated and compared.

AIM OF THE STUDY

This review aims to summarize the current status of ethnopharmacological uses, phytochemistry, pharmacology, clinical applications, and pharmacokinetics of the genus Ribes to better understand the therapeutic potential of the genus Ribes in the future and hope to provide a relatively novel perspective for further clinical application on the genus.

MATERIALS AND METHODS

The literature on Ribes was collected through a series of scientific search engines including Elsevier, ACS, Springer, Web of Science, PubMed, Google Scholar, Baidu Scholar, Wiley, China National Knowledge Infrastructure (CNKI) and books.

RESULTS

Ribes species have been used for detoxification, glaucoma, cardiovascular disease, stomachache, hepatitis, hyperlipidemia, hypertension and other ailments. These plants mainly contain phenolic glycosides, flavonoids, proanthocyanidins, polysaccharides, etc. Most traditional uses are related to biological activity and have been confirmed by modern research. Pharmacological studies in vitro and in vivo revealed that the extracts and pure compounds possessed significant hypolipidemic, antioxidant, anti-inflammatory, antitumor, antibacterial, and antiviral activity, eyesight protection and other effects.

CONCLUSIONS

The traditional uses, phytochemistry, pharmacology, pharmacokinetics, and clinical applications described in this article explained that the Ribes species has numerous activities, and these findings will promote further action in the area of mechanism research. However, very few preclinical and clinical studies have focused on the toxicology and pharmacokinetics of crude extracts and pure compounds from the genus Ribes. Moreover, several clinical evidence to support the health benefits of Ribes plants. The development of new medicines based on Ribes species as ingredients may be restricted. The pharmacological activity, clinical efficacy and safety of Ribes species need to be verified by systematic and comprehensive preclinical studies and clinical trials.